Expressed prostatic secretion biomarkers improve stratification of NCCN active surveillance candidates: Performance of secretion capacity and TMPRSS2:ERG models

Journal of Urology

Volumn 191, Issue 1, 2014, Pages 220-226

  Whelan, Christopher ^a   Kawachi, Mark ^a   Smith, David D ^b   Linehan, Jennifer ^a   Babilonia, Gail ^a   Mejia, Rosa ^c   Wilson, Timothy ^a   Smith, Steven S ^a,d  

^a Division of Urology and Urological Oncology   (United States)

^b Division of Biostatistics   (United States)

^c City of Hope   (United States)

^d CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

bodily secretions; neoplasm staging; prostate; prostatic neoplasms; risk

Indexed keywords

MESSENGER RNA; PROSTATE SPECIFIC ANTIGEN; RNA; THIOREDOXIN REDUCTASE 1; TUMOR MARKER; BIOLOGICAL MARKER; PROTEIN; TRANSMEMBRANE PROTEASE SERINE 2; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CANCER RISK; CANCER STAGING; CLINICAL EFFECTIVENESS; DISEASE SURVEILLANCE; GENE EXPRESSION; HUMAN; MAJOR CLINICAL STUDY; MALE; NATIONAL HEALTH ORGANIZATION; PATIENT SELECTION; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE SECRETION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RISK FACTOR; ROBOTICS; CANCER EPIDEMIOLOGY; CANCER SURGERY; ELECTRORETINOGRAM; HUMAN TISSUE; PREDICTIVE VALUE; PROSTATECTOMY; ROBOT ASSISTED SURGERY; TISSUE SECTION;

ACTIVE SURVEILLANCE; AS; BODILY SECRETIONS; DIGITAL RECTAL EXAMINATION; DRE; ECE; EPS; EXPRESSED PROSTATIC SECRETION; EXTRACAPSULAR EXTENSION; NEOPLASM STAGING; PCA; PCA3; PCR; POLYMERASE CHAIN REACTION; PROSTATE; PROSTATE CANCER; PROSTATE CANCER ANTIGEN 3 (NONPROTEIN CODING); PROSTATE SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; PSA; QPCR; QUANTITATIVE PCR; RISK; THIOREDOXIN REDUCTASE 1; TMPRSS2:ERG; TRANSMEMBRANE PROTEASE, SERINE 2 GENE FUSION WITH V-ETS ERYTHROBLASTOSIS VIRUS E26 ONCOGENE LIKE (AVIAN) GENE; TXNRD1;

ANTIGENS, NEOPLASM; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; ONCOGENE PROTEINS, FUSION; PRACTICE GUIDELINES AS TOPIC; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RISK ASSESSMENT; RISK FACTORS; RNA, MESSENGER; THIOREDOXIN REDUCTASE 1; TUMOR MARKERS, BIOLOGICAL; WATCHFUL WAITING;

EID: 84890126344     PISSN: 00225347     EISSN: 15273792     Source Type: Journal    
DOI: 10.1016/j.juro.2013.05.019     Document Type: Article

References (30)

1. National Cancer Institute: Prostate Cancer. Available at http://www.cancer.gov/cancertopics/types/prostate. Accessed April 2008.
2. G.J. O'Dowd, M.C. Miller, and R. Orozco Analysis of repeated biopsy results within 1 year after a noncancer diagnosis Urology 55 2000 553
3. H.G. Welch, and P.C. Albertsen Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986-2005 J Natl Cancer Inst 101 2009 1325
4. F.H. Schroder, J. Hugosson, and M.J. Roobol Screening and prostate-cancer mortality in a randomized European study N Engl J Med 360 2009 1320
5. L. Esserman, Y. Shieh, and I. Thompson Rethinking screening for breast cancer and prostate cancer JAMA 302 2009 1685
6. S. Loeb, K.A. Roehl, and B.T. Helfand Complications of open radical retropubic prostatectomy in potential candidates for active monitoring Urology 72 2008 887
7. A.V. D'Amico, R. Whittington, and S.B. Malkowicz Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer JAMA 280 1998 969
8. R. Choo, L. Klotz, and C. Danjoux Feasibility study: watchful waiting for localized low to intermediate grade prostate carcinoma with selective delayed intervention based on prostate specific antigen, histological and/or clinical progression J Urol 167 2002 1664
9. L. Klotz, L. Zhang, and A. Lam Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer J Clin Oncol 28 2010 126
10. M.C. Smaldone, J.E. Cowan, and P.R. Carroll Eligibility for active surveillance and pathological outcomes for men undergoing radical prostatectomy in a large, community based cohort J Urol 183 2010 138
11. J.I. Epstein, P.C. Walsh, and M. Carmichael Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer JAMA 271 1994 368
12. H.B. Carter Management of low (favourable)-risk prostate cancer BJU Int 108 2011 1684
13. M. Nazmy, C. Lau, and T. Wilson Gleason score upgrading in NCCN very low risk classification prostate cancer patients J Urol 187 2012 e284
14. J. Tosoian, and S. Loeb PSA and beyond: the past, present, and future of investigative biomarkers for prostate cancer Sci World J 10 2010 1919
15. L.J. Sokoll, M.G. Sanda, and Z. Feng A prospective, multicenter, National Cancer Institute Early Detection Research Network study of [-2]proPSA: improving prostate cancer detection and correlating with cancer aggressiveness Cancer Epidemiol Biomarkers Prev 19 2010 1193
16. I.M. Thompson, and D.P. Ankerst Prostate-specific antigen in the early detection of prostate cancer CMAJ 176 2007 1853
17. A.E. Ross, S. Loeb, and P. Landis Prostate-specific antigen kinetics during follow-up are an unreliable trigger for intervention in a prostate cancer surveillance program J Clin Oncol 28 2010 2810
18. E. Lechevallier, C. Eghazarian, and J.C. Ortega Effect of digital rectal examination on serum complexed and free prostate-specific antigen and percentage of free prostate-specific antigen Urology 54 1999 857
19. S.M. Aubin, J. Reid, and M.J. Sarno PCA3 molecular urine test for predicting repeat prostate biopsy outcome in populations at risk: validation in the placebo arm of the dutasteride REDUCE trial J Urol 184 2010 1947
20. J.P. Clark, K.W. Munson, and J.W. Gu Performance of a single assay for both type III-Type VI TMPRSS2:ERG fusions in non-invasive prediction of prostate biopsy outcome Clin Chem 54 2008 2007
21. B. Laxman, D.S. Morris, and J. Yu A first-generation multiplex biomarker analysis of urine for the early detection of prostate cancer Cancer Res 68 2008 645
22. S.A. Tomlins, S.M. Aubin, and J. Siddiqui Urine TMPRSS2:ERG fusion transcript stratifies prostate cancer risk in men with elevated serum PSA Sci Transl Med 3 2011 94ra72
23. M.L. Gonzalgo, C.P. Pavlovich, and S.M. Lee Prostate cancer detection by GSTP1 methylation analysis of postbiopsy urine specimens Clin Cancer Res 9 2003 2673
24. L.E. Crocitto, D. Korns, and L. Kretzner Prostate cancer molecular markers GSTP1 and hTERT in expressed prostatic secretions as predictors of biopsy results Urology 64 2004 821
25. K. Munson, J. Clark, and K. Lamparska-Kupsik Recovery of bisulfite-converted genomic sequences in the methylation-sensitive QPCR Nucleic Acids Res 35 2007 2893
26. C. Whelan, L. Crocitto, and M. Kawachi The influence of PSA-RNA yield on the analysis of expressed prostatic secretions (EPS) for prostate cancer diagnosis Can J Urol 20 2013 6597
27. E.M. Singer, L.E. Crocitto, and L.M. Weiss Biomarker identification with ligand-targeted nucleoprotein assemblies Nanomedicine 6 2011 659
28. E.J. Whitman, J. Groskopf, and A. Ali PCA3 score before radical prostatectomy predicts extracapsular extension and tumor volume J Urol 180 2008 1975
29. J.J. Tosoian, S. Loeb, and A. Kettermann Accuracy of PCA3 measurement in predicting short-term biopsy progression in an active surveillance program J Urol 183 2010 534
30. T.J. Wilt, M.K. Brawer, and K.M. Jones Radical prostatectomy versus observation for localized prostate cancer N Engl J Med 367 2012 203